<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:bf8d627f-479a-48ca-b9d6-ef2b3d3399c8"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="83da9e4b-5f31-4133-b6f5-edbf37f638b0"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-06-07T20:19:06Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:eff2c7c9-41a4-4231-a8d0-15845062e492"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
              
              <contained>
                          <Binary>
                            <id value="stylesheet0"/>
                            <!-- example format -->
                            <contentType value="stylesheet/css"/>
                            <!-- data is base 64 encoded, actual bytes of the image png file -->
                            <data value="<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#243F60;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#243F60;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:#404040;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-link:"Title Char";
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-link:"Title Char";
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-link:"Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:26.0pt;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:#4F81BD;
	letter-spacing:.75pt;
	font-style:italic;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin:0in;
	text-indent:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.8in;
	margin-bottom:0in;
	margin-left:.8in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4F81BD;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.5pt;
	font-family:Consolas;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:Consolas;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Cambria",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Cambria",serif;
	color:#243F60;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Cambria",serif;
	color:#243F60;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Cambria",serif;
	color:#404040;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Times New Roman",serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Times New Roman",serif;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Times New Roman",serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:Consolas;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:Consolas;}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:Consolas;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:normal;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	color:#17365D;
	letter-spacing:.25pt;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Times New Roman",serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;
	color:#4F81BD;
	letter-spacing:.75pt;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"/>
                          </Binary>
                        </contained>
                        <!-- this exension is necessary per image -->
                        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
                          <valueReference>
                            <reference value="#stylesheet0"/>
                          </valueReference>
                        </extension>
              
              <status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p align="center" class="MsoNormal" style="text-align:center"></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><span lang="EN-GB" style="color:black">Ovaleap 300 IU/0.5 mL solution for injection</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><span lang="EN-GB" style="color:black">Ovaleap 450 IU/0.75 mL solution for injection</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><span lang="EN-GB" style="color:black">Ovaleap 900 IU/1.5 mL solution for injection</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Each mL of the solution contains 600 IU (equivalent to 44 micrograms) follitropin alfa*.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 300 IU/0.5 mL solution for injection</span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Each cartridge contains 300 IU (equivalent to 22 micrograms) follitropin alfa in 0.5 mL solution for injection.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 450 IU/0.75 mL solution for injection</span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Each cartridge contains 450 IU (equivalent to 33 micrograms) follitropin alfa in 0.75 mL solution for injection.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 900 IU/1.5 mL solution for injection</span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Each cartridge contains 900 IU (equivalent to 66 micrograms) follitropin alfa in 1.5 mL solution for injection.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">*Follitropin alfa</span><span lang="EN-GB" style="color:black"> (recombinant human follicle‑stimulating hormone [r‑hFSH]) is produced in Chinese Hamster Ovary Cells (CHO DHFR<sup>-</sup>) by recombinant DNA technology.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB" style='font-family:"TimesNewRomanPSMT",serif'>Excipient(s) with known effect:</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Ovaleap contains 0.02 mg per mL of benzalkonium chloride</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Ovaleap </span><span lang="EN-GB" style="color:black">contains </span><span lang="EN-GB" style="color:black">10.0 mg per mL of benzyl alcohol</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">For the full list of excipients, see section 6.1.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><span lang="EN-GB" style="color:black">Solution for injection (injection).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Clear, colourless solution.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The pH of the solution is 6.8-7.2.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB" style="color:black">In adult women</span></u></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="EN-GB" style="color:black">•        Anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as <i>in vitro </i>fertilisation (IVF), gamete intra-fallopian transfer and zygote intra‑fallopian transfer.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        Ovaleap in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level &lt; 1.2 IU/L.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB" style="color:black">In adult men</span></u></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;page-break-after: avoid"><span lang="EN-GB" style="color:black">•        Ovaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hCG) therapy.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Treatment with follitropin alfa should be initiated under the supervision of a physician experienced in the treatment of fertility disorders.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black">Posology</span></u></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The dose recommendations given for follitropin alfa are those in use for urinary FSH. Clinical assessment of follitropin alfa indicates that its daily doses, regimens of administration and treatment monitoring procedures should not be different from those currently used for urinary FSH‑containing medicinal products. It is advised to adhere to the recommended starting doses indicated below.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Comparative clinical studies have shown that on average patients require a lower cumulative dose and shorter treatment duration with follitropin alfa compared with urinary FSH. Therefore, it is considered appropriate to give a lower total dose of follitropin alfa than generally used for urinary FSH, not only in order to optimise follicular development but also to minimise the risk of unwanted ovarian hyperstimulation (see section 5.1).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Women with anovulation (including polycystic ovarian syndrome)</span></u></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Follitropin alfa may be given as a course of daily injections. In menstruating women treatment should commence within the first 7 days of the menstrual cycle.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">A commonly used regimen commences at 75‑150 IU FSH daily and is increased preferably by 37.5 or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain an adequate, but not excessive, response. Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion. The maximal daily dose is usually not higher than 225 IU FSH. If a patient fails to respond adequately after 4 weeks of treatment, that cycle should be abandoned and the patient should undergo further evaluation after which she may recommence treatment at a higher starting dose than in the abandoned cycle.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">When an optimal response is obtained, a single injection of 250 micrograms recombinant human choriogonadotropin alfa (r-hCG) or 5,000 IU up to 10,000 IU hCG should be administered 24‑48 hours after the last follitropin alfa injection. The patient is recommended to have coitus on the day of, and the day following, hCG administration. Alternatively intrauterine insemination (IUI) may be performed.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">If an excessive response is obtained, treatment should be stopped and hCG withheld (see section 4.4). Treatment should recommence in the next cycle at a dose lower than that of the previous cycle.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="EN-GB" style="color:black">Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other ART</span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">A commonly used regimen for superovulation involves the administration of 150‑225 IU of follitropin alfa daily, commencing on days 2 or 3 of the cycle. Treatment is continued until adequate follicular development has been achieved (as assessed by monitoring of serum oestrogen concentrations and/or ultrasound examination), with the dose adjusted according to the patient’s response, to usually not higher than 450 IU daily. In general adequate follicular development is achieved on average by the tenth day of treatment (range 5 to 20 days).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">A single injection of 250 micrograms r‑hCG or 5,000 IU up to 10,000 IU hCG is administered 24‑48 hours after the last follitropin alfa injection to induce final follicular maturation.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Down‑regulation with a gonadotropin‑releasing hormone (GnRH) agonist or antagonist is now commonly used in order to suppress the endogenous LH surge and to control tonic levels of LH. In a commonly used protocol, follitropin alfa is started approximately 2 weeks after the start of agonist treatment, both being continued until adequate follicular development is achieved. For example, following two weeks of treatment with an agonist, 150‑225 IU follitropin alfa are administered for the first 7 days. The dose is then adjusted according to the ovarian response.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Overall experience with IVF indicates that in general the treatment success rate remains stable during the first four attempts and gradually declines thereafter.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Women with anovulation resulting from severe LH and FSH deficiency</span></u></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In LH and FSH deficient women (hypogonadotropic hypogonadism), the objective of follitropin alfa therapy in association with lutropin alfa is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of hCG. Follitropin alfa should be given as a course of daily injections simultaneously with lutropin alfa. Since these patients are amenorrhoeic and have low endogenous oestrogen secretion, treatment can commence at any time.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">A recommended regimen commences at 75 IU of lutropin alfa daily with 75‑150 IU FSH. Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and oestrogen response.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">If an FSH dose increase is deemed appropriate, dose adaptation should preferably be after 7‑14 day intervals and preferably by 37.5‑75 IU increments. It may be acceptable to extend the duration of stimulation in any one cycle to up to 5 weeks.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">When an optimal response is obtained, a single injection of 250 micrograms r‑hCG or 5,000 IU up to 10,000 IU hCG should be administered 24‑48 hours after the last follitropin alfa and lutropin alfa injections. The patient is recommended to have coitus on the day of, and on the day following, hCG administration. Alternatively, IUI may be performed.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Luteal phase support may be considered since lack of substances with luteotropic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">If an excessive response is obtained, treatment should be stopped and hCG withheld. Treatment should recommence in the next cycle at a dose of FSH lower than that of the previous cycle.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Men with hypogonadotropic hypogonadism</span></u></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Follitropin alfa should be given at a dose of 150 IU three times a week, concomitantly with hCG, for a minimum of 4 months. If after this period, the patient has not responded, the combination treatment may be continued; current clinical experience indicates that treatment for at least 18 months may be necessary to achieve spermatogenesis.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="EN-GB" style="color:black">Special population</span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB" style="color:black">Elderly population</span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">There is no relevant use of follitropin alfa in the elderly population. Safety and effectiveness of follitropin alfa in elderly patients have not been established.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black">Renal or hepatic impairment</span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Safety, efficacy and pharmacokinetics of follitropin alfa in patients with renal or hepatic impairment have not been established.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB" style="color:black">Paediatric population</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">There is no relevant use of follitropin alfa in the paediatric population.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Method of administration</span></u></i></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Ovaleap is intended for subcutaneous use. The first injection should be performed under direct medical supervision. Self-administration should only be performed by patients who are well motivated, adequately trained and have access to expert advice.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">As the multidose cartridge is intended for several injections, clear instructions should be provided to the patients to avoid misuse of the medicine.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The Ovaleap cartridge is designed for use in conjunction with the Ovaleap Pen only, which is separately available. For instructions on the administration with the<a name="OLE_LINK3"> Ovaleap Pen</a>, see section 6.6.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        Hypersensitivity to the active substance follitropin alfa, FSH or to any of the excipients</span><span lang="EN-GB" style="color:black">listed in section 6.1;</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        tumours of the hypothalamus or pituitary gland;</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        ovarian enlargement or ovarian cyst not due to polycystic ovarian syndrome;</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        gynaecological haemorrhages of unknown aetiology;</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        ovarian, uterine or mammary carcinoma.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">Ovaleap must not be used when an effective response cannot be obtained, such as:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        primary ovarian failure;</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        malformations of sexual organs incompatible with pregnancy;</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        fibroid tumours of the uterus incompatible with pregnancy;</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"><span lang="EN-GB" style="color:black">•        primary testicular insufficiency.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"></p><p class="MsoNormal"><i><u><span lang="EN-GB">Traceability</span></u></i></p><p class="MsoNormal"><span lang="EN-GB">In order to improve the traceability of biological medicinal products, the trade name and batch number of the administered medicinal product should be clearly recorded in the patient file.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">General</span></u></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Follitropin alfa is a potent gonadotropic substance capable of causing mild to severe adverse reactions and should only be used by physicians who are thoroughly familiar with infertility problems and their management.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Gonadotropin therapy requires a certain time commitment by physicians and supportive health professionals, as well as the availability of appropriate monitoring facilities. In women, safe and effective use of follitropin alfa calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis. There may be a degree of interpatient variability in response to FSH administration, with a poor response to FSH in some patients and exaggerated response in others. The lowest effective dose in relation to the treatment objective should be used in both men and women.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="EN-GB" style="color:black">Porphyria</span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Patients with porphyria or a family history of porphyria should be closely monitored during treatment with follitropin alfa. Deterioration or a first appearance of this condition may require cessation of treatment.</span></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black"></span></u></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Treatment in women</span></u></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Before starting treatment, the couple’s infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated. In particular, patients should be evaluated for hypothyroidism, adrenocortical deficiency, hyperprolactinemia and appropriate specific treatment given.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Patients undergoing stimulation of follicular growth, whether as treatment for anovulatory infertility or ART procedures, may experience ovarian enlargement or develop hyperstimulation. Adherence to recommended follitropin alfa dose and regimen of administration and careful monitoring of therapy will minimise the incidence of such events. For accurate interpretation of the indices of follicle development and maturation, the physician should be experienced in the interpretation of the relevant tests.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In clinical trials, an increase of the ovarian sensitivity to follitropin alfa was shown when administered with lutropin alfa. If an FSH dose increase is deemed appropriate, dose adaptation should preferably be at 7‑14 day intervals and preferably with 37.5‑75 IU increments.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">No direct comparison of follitropin alfa/LH versus human menopausal gonadotropin (hMG) has been performed. Comparison with historical data suggests that the ovulation rate obtained with follitropin alfa/LH is similar to that obtained with hMG.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Ovarian Hyperstimulation Syndrome (OHSS)</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">A certain degree of ovarian enlargement is an expected effect of controlled ovarian stimulation. It is more commonly seen in women with polycystic ovarian syndrome and usually regresses without treatment.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In distinction to uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself with  increasing degrees of severity. It comprises marked ovarian enlargement, high serum sex steroids and an increase in vascular permeability which can result in an accumulation of fluid in the peritoneal, pleural and, rarely, in the pericardial cavities.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The following symptomatology may be observed in severe cases of OHSS: abdominal pain, abdominal distension, severe ovarian enlargement, weight gain, dyspnoea, oliguria and gastrointestinal symptoms including nausea, vomiting and diarrhoea. Clinical evaluation may reveal hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, haemoperitoneum, pleural effusions, hydrothorax, or acute pulmonary distress. Very rarely, severe OHSS may be complicated by ovarian torsion or thromboembolic events such as pulmonary embolism, ischaemic stroke or myocardial infarction.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Independent risk factors for developing OHSS include polycystic ovarian syndrome high absolute or rapidly rising serum oestradiol levels (e.g. &gt; 900 pg/mL or &gt; 3,300 pmol/L in anovulation; &gt; 3,000 pg/mL or &gt; 11,000 pmol/L in ART) and large number of developing ovarian follicles (e.g. &gt; 3 follicles of ≥ 14 mm in diameter in anovulation; ≥ 20 follicles of ≥ 12 mm in diameter in ART).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Adherence to recommended follitropin alfa dose and regimen of administration can minimise the risk of ovarian hyperstimulation (see sections 4.2 and 4.8). Monitoring of stimulation cycles by ultrasound scans as well as oestradiol measurements are recommended to early identify risk factors.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">There is evidence to suggest that hCG plays a key role in triggering OHSS and that the syndrome may be more severe and more protracted if pregnancy occurs. Therefore, if signs of ovarian hyperstimulation occur such as serum oestradiol level &gt; 5,500 pg/mL or &gt; 20,200 pmol/L and/or ≥ 40 follicles in total, it is recommended that hCG be withheld and the patient be advised to refrain from coitus or to use barrier contraceptive methods for at least 4 days. OHSS may progress rapidly (within 24 hours) or over several days to become a serious medical event. It most often occurs after hormonal treatment has been discontinued and reaches its maximum at about 7 to 10 days following treatment. Therefore, patients should be followed for at least 2 weeks after hCG administration.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In ART, aspiration of all follicles prior to ovulation may reduce the occurrence of hyperstimulation.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Mild or moderate OHSS usually resolves spontaneously. If severe OHSS occurs, it is recommended that gonadotropin treatment be stopped if still ongoing and that the patient be hospitalised and appropriate therapy be started.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Multiple pregnancy</span></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">In patients undergoing ovulation induction, the incidence of multiple pregnancy is increased compared with natural conception. The majority of multiple conceptions are twins. Multiple pregnancy, especially of high order, carries an increased risk of adverse maternal and perinatal outcomes.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">To minimise the risk of multiple pregnancy, careful monitoring of ovarian response is recommended.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In patients undergoing ART procedures the risk of multiple pregnancy is related mainly to the number of embryos replaced, their quality and the patient age.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The patients should be advised of the potential risk of multiple births before starting treatment.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Pregnancy loss</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing stimulation of follicular growth for ovulation induction or ART than following natural conception.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Ectopic pregnancy</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Women with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments. The prevalence of ectopic pregnancy after ART, was reported to be higher than in the general population.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Reproductive system neoplasms</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple treatment regimens for infertility treatment. It is not yet established whether or not treatment with gonadotropins increases the risk of these tumours in infertile women.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Congenital malformation</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The prevalence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and multiple pregnancies.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><span lang="EN-GB" style="color:black">Thromboembolic events</span></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thromboembolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events. In these women, the benefits of gonadotropin administration need to be weighed against the risks. It should be noted however that pregnancy itself as well as OHSS also carry an increased risk of thromboembolic events.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Treatment in men</span></u></i></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Elevated endogenous FSH levels are indicative of primary testicular failure. Such patients are unresponsive to follitropin alfa/hCG therapy. Follitropin alfa should not be used when an effective response cannot be obtained.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Semen analysis is recommended 4 to 6 months after the beginning of treatment as part of the assessment of the response.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="EN-GB">Benzalkonium chloride content</span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Ovaleap contains 0.02 mg/mL of benzalkonium chloride</span></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="EN-GB"></span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="EN-GB">Benzyl alcohol content</span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Ovaleap contains </span><span lang="EN-GB">10.0 mg per mL benzyl alcohol</span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB">Benzyl alcohol may cause allergic reactions.</span></u></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment as well as in pregnant women or while breast-feeding, because of the risk of accumulation and toxicity (metabolic acidosis).</span></p><p class="MsoNormal" style="page-break-after:avoid"><u><span lang="EN-GB"></span></u></p><p class="MsoNormal" style="page-break-after:avoid"><i><u><span lang="EN-GB">Sodium content</span></u></i></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Ovaleap contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium­free”.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Concomitant use of follitropin alfa with other medicinal products used to stimulate ovulation (e.g. hCG, clomifene citrate) may potentiate the follicular response, whereas concurrent use of a GnRH agonist or antagonist to induce pituitary desensitisation may increase the dose of follitropin alfa needed to elicit an adequate ovarian response. No other clinically significant medicinal product interaction has been reported during follitropin alfa therapy.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Pregnancy</span></u></i></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">There is no indication for use of Ovaleap during pregnancy. Data on a limited number of exposed pregnancies (less than 300 pregnancy outcomes) indicate no malformative or foeto/neonatal toxicity of follitropin alfa.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">No teratogenic effect has been observed in animal studies (see section 5.3). In case of exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of follitropin alfa.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Breast‑feeding</span></u></i></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black"></span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Ovaleap is not indicated during breast‑feeding.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Fertility</span></u></i></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black"></span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Ovaleap is indicated for use in infertility (see section 4.1).</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Ovaleap has no or negligible influence on the ability to drive and use machines.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Summary of the safety profile</span></u></i></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The most commonly reported adverse reactions are headache, ovarian cysts and local injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Mild or moderate OHSS has been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Severe OHSS is uncommon (see section 4.4).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Thromboembolism may occur very rarely (see section 4.4).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Tabulated list of adverse reactions</span></u></i></p><p class="MsoNormal" style="margin-left:85.05pt;text-indent:-85.05pt"><span lang="EN-GB">The adverse reactions are ranked under heading of frequency using the following convention: very</span></p><p class="MsoNormal" style="margin-left:85.05pt;text-indent:-85.05pt"><span lang="EN-GB">common (≥1/10), common (≥1/100 to &lt;1/10), uncommon (≥1/1,000 to &lt;1/100), rare (≥1/10,000 to</span></p><p class="MsoNormal" style="margin-left:85.05pt;text-indent:-85.05pt"><span lang="EN-GB">&lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data). Within</span></p><p class="MsoNormal" style="margin-left:85.05pt;text-indent:-85.05pt"><span lang="EN-GB">each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Treatment in women</span></i></p><p class="MsoNormal" style="page-break-after:avoid"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <tr> <td colspan="3" style="width:460.6pt;border:none;   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="614"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table   1: Adverse reactions in women</span></b></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">System   organ class</span></b></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Frequency</span></b></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Adverse   reaction</span></b></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Immune   system disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very rare</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Mild to severe hypersensitivity reactions, including anaphylactic   reactions and shock</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Nervous   system disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very common</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Headache</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Vascular disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very rare</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Thromboembolism (both in association with and separate   from OHSS)</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Respiratory, thoracic and mediastinal disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very rare</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Exacerbation or aggravation of asthma</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Gastrointestinal disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Common:</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Abdominal pain, abdominal distension, abdominal   discomfort, nausea, vomiting, diarrhoea</span></p> </td> </tr> <tr> <td rowspan="4" style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Reproductive system and breast disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very common</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Ovarian cysts</span></p> </td> </tr> <tr> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Common</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Mild or moderate OHSS (including associated   symptomatology)</span></p> </td> </tr> <tr> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Uncommon</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Severe OHSS (including associated symptomatology) (see   section 4.4)</span></p> </td> </tr> <tr> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Rare</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Complication of severe OHSS</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">General   disorders and administration site conditions</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very common</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Injection site reactions (e.g. pain, erythema, haematoma,   swelling and/or irritation at the site of injection)</span></p> </td> </tr> </table><p class="MsoNormal" style="margin-left:85.05pt;text-indent:-85.05pt"></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif; color:black'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/><p class="MsoNormal"></p><p class="MsoNormal" style="margin-left:85.05pt;text-indent:-85.05pt"></p><p class="MsoNormal" style="margin-left:85.05pt;text-indent:-85.05pt"><i><span lang="EN-GB" style="color:black">Treatment in men</span></i></p><p class="MsoNormal" style="margin-left:85.05pt;text-indent:-85.05pt"></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse:collapse;border:none"> <tr> <td colspan="3" style="width:460.6pt;border:none;   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt" valign="top" width="614"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Table   2: Adverse reactions in men</span></b></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">System   organ class</span></b></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Frequency</span></b></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Adverse   reaction</span></b></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">Immune   system disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very rare</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Mild to severe hypersensitivity reactions, including   anaphylactic reactions and shock</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Respiratory, thoracic and mediastinal disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very rare</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Exacerbation or aggravation of asthma</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Skin and subcutaneous tissue disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Common:</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Acne</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Reproductive system and breast disorders</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Common</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Gynaecomastia, varicocele</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB">General   disorders and administration site conditions</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Very common</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Injection site reactions (e.g. pain, erythema, haematoma,   swelling and/or irritation at the site of injection)</span></p> </td> </tr> <tr> <td style="width:153.5pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><i><span lang="EN-GB" style="color:black">Investigations</span></i></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Common</span></p> </td> <td style="width:153.55pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="205"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Weight gain</span></p> </td> </tr> </table><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB">Reporting of suspected adverse reactions</span></u></p><p class="MsoNormal"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="background:lightgrey">the national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="background:lightgrey">Appendix V</span></a></span><span lang="EN-GB">.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The effects of an overdose of follitropin alfa are unknown, nevertheless, there is a possibility that OHSS may occur (see section 4.4).</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Pharmacotherapeutic group: Sex hormones and modulators of the genital systems, gonadotropins, ATC code: G03GA05.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Ovaleap</span><span lang="EN-GB" style="color:black"> is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency </span><span lang="EN-GB"><a href="http://www.ema.europa.eu"><span style="color:black; text-decoration:none">http://www.ema.europa.eu</span></a><span style="color:black">.</span></span></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><i><u><span lang="EN-GB" style="color:black">Pharmacodynamic effects</span></u></i></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles. In women with anovulation, the object of follitropin alfatherapy is to develop a single mature Graafian follicle from which the ovum will be liberated after the administration of hCG.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Clinical efficacy and safety in women</span></u></i></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In clinical trials, patients with severe FSH and LH deficiency were defined by an endogenous serum LH level &lt; 1.2 IU/L as measured in a central laboratory. However, it should be taken into account that there are variations between LH measurements performed in different laboratories.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In clinical studies comparing r-hFSH (follitropin alfa) and urinary FSH in ART (see table 3 below) and in ovulation induction, follitropin alfa was more potent than urinary FSH in terms of a lower total dose and a shorter treatment period needed to trigger follicular maturation.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In ART, follitropin alfa at a lower total dose and shorter treatment period than urinary FSH, resulted in a higher number of oocytes retrieved when compared to urinary FSH.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Table 3: Results of study GF 8407 (randomised parallel group study comparing efficacy and safety of follitropin alfa with urinary FSH in ART)</span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:402.3pt;margin-left:5.4pt;border-collapse:collapse;border:none" width="536"> <tr> <td style="width:182.6pt;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal" style="page-break-after:avoid"></p> </td> <td style="width:106.3pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><span lang="EN-GB" style="color:black">follitropin   alfa</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">(n = 130)</span></p> </td> <td style="width:113.4pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid;text-autospace:none"><span lang="EN-GB" style="color:black">urinary FSH</span></p> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">(n = 116)</span></p> </td> </tr> <tr> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Number of oocytes retrieved</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">11.0 ± 5.9</span></p> </td> <td style="width:113.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">8.8 ± 4.8</span></p> </td> </tr> <tr> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Days of FSH stimulation required</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">11.7 ± 1.9</span></p> </td> <td style="width:113.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">14.5 ± 3.3</span></p> </td> </tr> <tr> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Total dose of FSH required (number of FSH 75 IU   ampoules)</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">27.6 ± 10.2</span></p> </td> <td style="width:113.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">40.7 ± 13.6</span></p> </td> </tr> <tr> <td style="width:182.6pt;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="243"> <p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Need to increase the dose (%)</span></p> </td> <td style="width:106.3pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="142"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">56.2</span></p> </td> <td style="width:113.4pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="151"> <p align="center" class="MsoNormal" style="text-align:center;page-break-after:   avoid"><span lang="EN-GB" style="color:black">85.3</span></p> </td> </tr> </table><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Differences between the 2 groups were statistically significant (p &lt; 0.05) for all criteria listed.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><i><u><span lang="EN-GB" style="color:black">Clinical efficacy and safety in men</span></u></i></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In men deficient in FSH, follitropin alfa administered concomitantly with hCG for at least 4 months induces spermatogenesis.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"></p><p class="MsoNormal" style="margin-right:-.1pt;page-break-after:avoid"><span lang="EN-GB" style="color:black">Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space with </span><span lang="EN-GB" style="color:black">an initial half-life of around 2 hours and eliminated from the body with a terminal half-life of about one day. The steady state volume of distribution and total clearance are 10 L and 0.6 L/h, respectively. One‑eighth of the follitropin alfa dose is excreted in the urine.</span></p><p class="MsoNormal" style="margin-right:-.1pt"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB" style="color:black">Following subcutaneous administration, the absolute bioavailability is about 70 %. Following repeated administration, follitropin alfa accumulates 3‑fold achieving a steady-state within 3‑4 days. In women whose endogenous gonadotropin secretion is suppressed, follitropin alfa has nevertheless been shown to effectively stimulate follicular development and steroidogenesis, despite unmeasurable LH levels. </span></p><p class="MsoNormal" style="margin-right:-.1pt"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB" style="color:black">Non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity and genotoxicity additional to that already stated in other sections of this SmPC.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Impaired fertility has been reported in rats exposed to pharmacological doses of follitropin alfa (≥ 40 IU/kg/day) for extended periods, through reduced fecundity.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Given in high doses (≥ 5 IU/kg/day) follitropin alfa caused a decrease in the number of viable foetuses without being a teratogen and dystocia similar to that observed with urinary Menopausal Gonadotropin (hMG). However, since Ovaleap is not indicated in pregnancy, these data are of limited clinical relevance.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="page-break-after:avoid"></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Sodium dihydrogen phosphate dihydrate</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Sodium hydroxide (2 M) (for pH adjustment)</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Mannitol</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Methionine</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Polysorbate 20</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Benzyl alcohol</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Benzalkonium chloride</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Water for injections</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:red">3</span><span lang="EN-GB" style="color:black"> years.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><u><span lang="EN-GB" style="color:black">Shelf life</span></u><u><span lang="EN-GB"> and storage conditions after first opening</span></u></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The cartridge in‑use in the pen may be stored for a maximum of 28 days. Do not store above 25 °C. The patient should write down in the patient diary provided with the Ovaleap Pen the date of first use.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The pen cap must be put back on the pen after each injection in order to protect from light.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Store in a refrigerator (2 °C ‑ 8 °C).</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Do not freeze.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Keep the cartridge in the outer carton in order to protect from light.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Before opening and within its shelf life, the medicinal product may be removed from the refrigerator, without being refrigerated again, for up to 3 months. Do not store above 25 °C. The medicinal product must be discarded if it has not been used after 3 months.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">For storage conditions after first opening of the medicinal product, see section 6.3.</span></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 300 IU/0.5 mL solution for injection</span></u></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cartridge (type I glass) with a rubber piston (bromobutyl rubber) and a crimp‑cap (aluminium) with a septum (bromobutyl rubber), containing 0.5 mL of solution.<br/> Injection needles (stainless steel; 0.33 mm x 12 mm, 29 G x ½")</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Pack size of 1 cartridge and 10 injection needles.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 450 IU/0.75 mL solution for injection</span></u></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cartridge (type I glass) with a rubber piston (bromobutyl rubber) and a crimp‑cap (aluminium) with a septum (bromobutyl rubber), containing 0.75 mL of solution..<br/> Injection needles (stainless steel; 0.33 mm x 12 mm, 29 G x ½")</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Pack size of 1 cartridge and 10 injection needles.</span></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"></p><p class="MsoNormal"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 900 IU/1.5 mL solution for injection</span></u></p><p class="MsoNormal" style="text-autospace:none"><span lang="EN-GB" style="color:black">Cartridge (type I glass) with a rubber piston (bromobutyl rubber) and a crimp‑cap (aluminium) with a septum (bromobutyl rubber), containing 1.5 mL of solution..<br/> Injection needles (stainless steel; 0.33 mm x 12 mm, 29 G x ½")</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Pack size of 1 cartridge and 20 injection needles.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal and other handling"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB">No special requirements for disposal.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">The solution must not be used if it contains particles or if the solution is not clear.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Ovaleap is designed for use in conjunction with the Ovaleap Pen only. The instructions for use of the pen must be followed carefully.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Each cartridge must be used by a single patient only.</span></p><p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Empty cartridges must not be refilled. Ovaleap cartridges are not designed to allow any other medicinal product to be mixed in the cartridges. Discard used needles immediately after injection.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="NL">Theramex Ireland Limited</span></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">3<sup>rd</sup> Floor, </span><span lang="NL">Kilmore House,</span></p><p class="MsoNormal"><span lang="NL">Park Lane, Spencer Dock,</span></p><p class="MsoNormal"><span lang="NL">Dublin 1</span></p><p class="MsoNormal"><span lang="NL">D01 YE64</span></p><p class="MsoNormal"><span lang="NL">Ireland</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBER(S) "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 300 IU/0.5 mL solution for injection</span></u></p><p class="MsoNormal"><span lang="EN-GB">EU/1/13/871/001</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 450 IU/0.75 mL solution for injection</span></u></p><p class="MsoNormal"><span lang="EN-GB">EU/1/13/871/002</span></p><p class="MsoNormal"></p><p class="MsoNormal" style="text-align:justify;text-justify:inter-ideograph; text-autospace:none"><u><span lang="EN-GB" style="color:black">Ovaleap 900 IU/1.5 mL solution for injection</span></u></p><p class="MsoNormal"><span lang="EN-GB">EU/1/13/871/003</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal"><span lang="EN-GB" style="color:black">Date of first authorisation: 27 September 2013.</span></p><p class="MsoNormal"><span lang="EN-GB">Date of latest renewal: 16 May 2018.</span></p><p class="MsoNormal"></p><p class="MsoNormal"></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal"></p><p class="MsoNormal" style="margin-right:-.1pt"><span lang="EN-GB">Detailed information on this medicinal product </span><span lang="EN-GB">is available on the website of the European Medicines Agency </span><span lang="EN-GB"><a href="http://www.ema.europa.eu"><span style="color:windowtext;text-decoration: none">http://www.ema.europa.eu</span></a></span><span lang="EN-GB">. </span></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>